EDIGENE INC.

In News

EdiGene and Arbor Biotechnologies Announce Worldwide Non-exclusive License Agreement to Advance Ex Vivo Engineered Cell Therapy Programs - Business Wire

Business Wire - Feb 08, 2022

EdiGene Raises Approximately USD 62 Million in Series B Plus Financing and Expands Operation Locations to Advance and Scale Up Clinical Translation of Gene Editing Technologies - SynBioBeta

SynBioBeta - Apr 22, 2021

EdiGene and Neukio to Develop iPSC-Derived NK Cell Therapies - BioInformant

BioInformant - Feb 21, 2022

Clinical Update: EdiGene Enrols First Patient in Phase 1 Trial for Transfusion-Dependent Beta Thalassemia - crisprmedicinenews.com

crisprmedicinenews.com - Sep 15, 2021

Chinese Biotech Firm EdiGene Nabs $67m From Sequoia, IDG, Others - Caixin Global

Caixin Global - Oct 14, 2020

Fujifilm invests in gene therapy startup - BioPharma Dive

BioPharma Dive - Dec 21, 2017

EdiGene Biotechnology Moves into New R&D Center at Waltham, Mass. to Advance Proprietary LEAPER™ Technology into Transformative in vivo RNA Editing Therapies - Business Wire

Business Wire - Nov 07, 2022

Gene-edited immune cells show promise for universal 'off-the-shelf' cancer therapy - Medical Xpress

Medical Xpress - Sep 08, 2025

Clinical Roundup: Gene-Edited Therapies for Beta Thalassemia - crisprmedicinenews.com

crisprmedicinenews.com - Jul 26, 2023

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment